Click on a filter below to refine your search. Remove a filter to broaden your search.
The GLI-Global differentiated all-cause mortality risk between normal spirometry and first grade of COPD in adjusted analyses.
Those receiving pulmonologist-directed treatment have less subsequent healthcare utilization for respiratory illness.
An increase was seen in prebronchodilator forced expiratory volume in one second with dupilumab versus placebo at weeks 12 and 52.
No reduction was seen in the number of self-reported exacerbations treated with oral corticosteroids, antibiotics or both.
The findings were for veterans with chronic obstructive pulmonary disease, heart failure or interstitial lung disease.
The findings were seen in older hospitalized patients with advanced chronic obstructive pulmonary disease, dementia or kidney failure.
Compared with matched nonusers, gabapentinoid users have an increased risk across indications of epilepsy, neuropathic pain and other chronic pain.
At 30 days after discharge, the mortality rate was 3.2% and skilled nursing facility use rate was 2.6%.
Virtual care is here to stay, so it is time we start working harder to make those solutions an option for everyone.
Active treatment lowered SBP, improved 6-minute walk test and improved measures of endothelial function.